Please provide your email address to receive an email when new articles are posted on . It is well known that HMG-CoA reductase inhibitors reduce LDL, a surrogate marker in atherosclerotic disease, as ...

May 19, 2011 (Charlottesville, Virginia) — Whereas statins appeared to halt atherosclerosis, ezetimibe (Zetia, Merck/Schering-Plough) was associated with an increase in plaque volume in peripheral ...

In this study, after a six- to eight-week washout period, patients with mixed hyperlipidemiaLDL cholesterol between 130 and 220 mg/dL (between 100 and 180 mg/dL for type 2 diabetics) and triglycerides ...

Ezetimibe is a nonstatin low-density lipoprotein cholesterol-lowering small molecule drug. Ezetimibe is the only currently FDA-approved approved member of the of intestinal cholesterol reuptake ...

(HealthDay)—Treatment with the lipid-lowering therapy ezetimibe/simvastatin is not associated with an increased risk of developing cancer or an increased risk of dying from cancer, according to ...

What to do: If your bottle of ezetimibe 10 mg tablets contains any perindopril 4 mg tablets, or if you are unsure, return it to your pharmacy immediately. If you are unable to return your tablets to ...

A recent simulation study published in the journal Scientific Reports analyzed representative data of over two million outpatients in Germany, in which the researchers reported that a combination of ...

The US Food and Drug Administration has declined to extend the indication for the cholesterol-lowering drug ezetimibe to include cardiovascular event reduction, the manufacturer has announced. Merck ...

A combination of simvastatin and ezetimibe (Vytorin) lowered cholesterol better than simvastatin alone, but it had no effect on arterial plaque in a major clinical trial. As a result, cardiologists ...

Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of ...

Moderate-intensity statin with ezetimibe combination therapy was confirmed to be effective on low-density lipoprotein cholesterol (LDL-C) reduction in patients at very high risk of atherosclerotic ...

(HealthDay News) — Treatment with the lipid-lowering therapy ezetimibe/simvastatin is not associated with an increased risk of developing cancer or an increased risk of dying from cancer, according to ...